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 Brain Metastases 
 Neuroendocrine tumors are considered to be the cause 
of brain metastases in 1.3–1.4% of all patients with brain 
metastases  [1, 2] . In patients with NETs, the incidence of 
brain metastases is estimated to be 1.5–5%  [3, 4] . This 
figure, however, is probably an underestimate since many 
patients do not undergo routine brain imaging as a com-
ponent of metastatic assessment. Brain metastases occur 
at different ages ranging from 11 to  1 80 years  [3, 5] . Ac-
cording to the largest report on 24 patients with brain 
metastases, the median age at diagnosis of brain metas-
tasis was 60 years (range 18–85). Median time from diag-
nosis of the primary tumor to detection of brain metas-
tases was 1.5 years (range 0–16), with both genders being 
similarly affected  [3] . Time intervals from removal of a 
bronchial carcinoid to occurrence of brain metastases of 
up to 25 years are reported  [6] .The spread of NET to the 
cerebrum has been reported in association with all pri-
mary tumor locations of the gastroenteropancreatic, 
bronchopulmonary and genitourinary system  [1, 7–16] . 
 Introduction 
 Epidemiology and Clinicopathological Features 
 Metastatic disease is a critical issue in the management 
of neuroendocrine tumors (NETs) and forms a key com-
ponent in the management of such patients. In general, 
the majority of metastases occur in the liver, lungs and 
bone; other sites are much rarer. Nevertheless, when pres-
ent, they pose substantial management issues and there-
fore require serious consideration. Rare metastatic sites 
include the brain, heart, ovaries, breast, thyroid, pancre-
as, skin, adrenal glands, kidney, spleen, orbit, retroperi-
toneum, testis and pituitary gland. This overview will fo-
cus primarily on metastatic lesions of the brain, heart and 
ovary.
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Nevertheless, bronchopulmonary NETs appear to be the 
dominant source of cerebral metastases  [11, 17]. Thus, in 
the largest series of brain metastases the primary tumor 
was located in the bronchi or lungs in 45 and 71% of the 
patients, respectively  [3, 4]. This observation is consistent 
with the experience documented in the 57 individual case 
reports published between 1962 and 2007 which identi-
fied the bronchopulmonary system as the primary tumor 
location in  1 50% of the patients. Since the histological 
type was not clearly defined in the published series, it is 
not clear if there is a specific propensity for metastasis 
based upon tumor grade or type. Based on the available 
information, it appears that both well-differentiated and 
poorly differentiated lesions may give rise to brain metas-
tases and are each responsible for 50% of the metastases. 
With respect to pulmonary NETs, it is reported that typ-
ical carcinoids  [18] , atypical carcinoids  [10] and large cell 
variants  [19] may produce brain metastases. In addition 
to the cerebral metastasis, advanced disease is evident at 
the time of diagnosis with 75% of the patients having 
lymph node metastases and 50% exhibiting liver metas-
tases  [3] . Other uncommon synchronous or metachro-
nous metastatic sites include the spine, adrenals, skin or 
breast. It is noteworthy that a minority of patients present 
with brain metastases as the initial symptom of their dis-
ease or as the only metastatic site  [1, 10, 20] .
 Cardiac Metastases 
 The incidence of cardiac metastases in patients with 
NETs is estimated to be  ! 1%, but is probably higher since 
the majority of patients do not undergo specific cardiac 
imaging procedures as part of the metastatic work-up and 
small myocardial lesions are only identified at autopsy. 
Cardiac metastases generally occur late in the course of 
the disease and are evident irrespective of carcinoid val-
vular disease. However, they are almost always associated 
with other metastases and liver involvement. In living 
and autopsy studies on patients with metastatic carcinoid 
neoplasia and concomitant carcinoid syndrome, approx-
imately 4.0–4.5% exhibit myocardial metastases  [21, 22] . 
In a series of 11 patients, cardiac metastases were diag-
nosed at autopsy in 45% of the patients. The mean size of 
the lesions was small (0.35 cm) in contrast to those de-
tected by echocardiography, which exhibited a mean size 
of 2.4 cm (range 1.2–4). The average age at diagnosis of 
myocardial metastases is 58.2 years (range 39–68 years) 
and the elapsed time between diagnosis of carcinoid syn-
drome and identification of cardiac metastases is 5.6  8 
3.9 years  [21] . Based on the current experience of 36 pub-
lished case reports in the literature, it is apparent that the 
majority of cardiac metastases originate from NET of the 
gastrointestinal tract  [21] . Other sites of the primary tu-
mor include the pancreas  [23] and bronchopulmonary 
system  [24, 25] , but in individual patients the location of 
the primary tumor is unknown  [26] . The occurrence of 
myocardial metastases has been described more often in 
patients with functioning tumors than in those with non-
functioning tumors, although the significance of this ob-
servation is unclear. Of note, the histological grade of the 
lesions associated with cardiac metastasis is predomi-
nantly well-differentiated neuroendocrine carcinoma.
 Ovarian Metastases 
 This is a rare event with more than 60 cases cited in 
the literature. The estimated incidence is approximately 
2%, but the number is probably underestimated. The 
source of ovarian NET metastases is usually ileal carci-
noid tumors; however, other primary tumor sites report-
ed include the jejunum, cecum, pancreas and appendix. 
It has been proposed that   2% of intestinal carcinoids
 1 1 cm in size are associated with ovarian metastases  [27, 
28] . Of note is the fact that they are usually bilateral in 
contrast to primary ovarian lesions, which are usually 
unilateral, and this constitutes a significant point in 
terms of differential diagnosis. Primary carcinoids of the 
ovary are unilateral and localized in   90% of the cases 
 [29] and are often associated with teratomatous elements 
within the tumor. In two reports of 17 and 35 cases, the 
median age at the time of detection of ovarian metastases 
was 57 years (range 44–77 and 21–82, respectively)  [27, 
30] . The size of the ovarian lesions varies and may range 
from microscopic foci to lesions  1 9 cm in size  [30] . Ap-
proximately 30% are identified at autopsy  [27] . Clinically, 
most patients have well-differentiated NETs with syn-
chronous hepatic metastatic disease and present with 
carcinoid syndrome. Multiple metachronous metastases 
occur in nearly all individuals with ovarian lesions and 
the entity is usually consistent with advanced disease. In 
addition, a substantial number (28–35%) exhibit exten-
sive peritoneal seeding. Apart from the small bowel as a 
primary tumor site, it is noteworthy that goblet-cell mu-
cinous carcinoids of the appendix may also be associated 
with ovarian metastases  [31, 32] . The mucinous subtype 
appears to be more aggressive and is consistent with the 
observation that appendiceal NETs classified as the gob-
let variety have a significantly worse prognosis than the 
usual nonmucinous variety  [33] .
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 Minimal Consensus Statements on Epidemiology and 
Clinicopathological Features 
The incidence of brain metastases is 1.5–5%, cardiac me-
tastases 1–4% and ovarian metastases   2%. There is no gen-
der preference for the occurrence of brain metastases. How-
ever, cardiac metastases appear to be more common in males. 
Broncho-pulmonary NETs are more likely to develop brain 
metastases, whereas midgut tumors are the usual source of 
cardiac and ovarian metastases. Both well-differentiated and 
poorly differentiated (50% each) bronchopulmonary tumors 
are associated with brain metastases. On the contrary, tumors 
that produce cardiac or ovarian metastases are usually well-
differentiated. The majority of individuals with brain, ovari-
an and cardiac metastases have an advanced disease stage. 
Cardiac and ovarian metastases are more commonly associ-
ated with carcinoid syndrome.
 
 Clinical Presentation 
 Brain metastases are associated with headaches in 
 1 95% of the patients. Personality changes and unstable 
gait are reported in up to 25%, cranial nerve deficits in 
more than 10% and seizures or nausea and emesis in less 
than 10% of the patients  [3] . Cardiac and ovarian metas-
tases are usually identified incidentally on imaging, but 
may contribute to the symptoms of carcinoid syndrome. 
Cardiac metastases rarely display clinical symptoms 
( ! 30%) but when present include dyspnea, arrhythmias or 
accentuation of the carcinoid syndrome  [22, 24, 34–38] .
 Prognosis 
 In the largest series described, comprising 11 and 24 
patients, respectively, the median survival time from di-
agnosis of brain metastases was 7–10 months, although 
occasionally long-term survivors have been reported. 
Survival times of up to 11 years have been reported and 
between 33 and 42% of the patients survived  1 1 year  [3, 
4] . Overall survival rates are  ! 20% at 2 years and  ! 5% at 
5 years. Survival rates in patients with cardiac metastases, 
although of rather short duration, are overall better than 
for brain metastases. In 35 patients with ovarian metas-
tases, a 5-year survival rate of 25% was reported in 1974, 
while a recent report indicates a projected 5-year surviv-
al of 94%  [27, 30] . Although no clear explanation for this 
is apparent, it is likely that advances in diagnosis and 
treatment have led to earlier detection and better therapy, 
thus providing an optimization of the outcome of the 
condition. Current assessment suggests that patients with 
ovarian metastases exhibit survival rates that are proba-
bly comparable to individuals with liver metastases.
Minimal Consensus Statements on Clinical
Presentation and Prognosis
 The leading symptom of brain metastases is headache. The 
median survival is less than 10 months with a 1-year survival 
rate of  ! 40%. Ovarian and cardiac metastases do not have spe-
cific symptoms and are usually identified incidentally. In gen-
eral, survival rates are comparable to liver metastases but the 
outcome is worse with cardiac metastases. 
 
Hereditary Tumor Syndromes 
 No hereditary predisposition has been described for 
brain, cardiac or ovarian metastases.
 Diagnostic Procedures 
 Imaging 
 Brain metastases are usually identified on MRI or CT 
scanning. Octreoscan and  68 Ga-DOTATOC-PET/CT 
may be helpful in the early detection of brain metastases, 
provided that the histological tumor type is well-differ-
entiated. The data are currently inadequate to determine 
the relative efficacy of the individual methods. Since 
poorly differentiated bronchopulmonary tumors are 
considered at greater risk of developing brain metastases, 
brain MRI is the recommended imaging modality, analo-
gous to the strategy for small cell lung cancer. Most met-
astatic myocardial lesions are found by 2D echocardio-
graphic screening during evaluation of valvular carci-
noid heart disease. Smaller cardiac lesions are often 
missed, since the spatial resolution of this technique is
  1 cm  [21] . Some cardiac metastases only present as wall 
thickening and may be difficult to identify with echocar-
diography. As a single method, MRI is superior to echo-
cardiography in the detection and quantification of car-
diac metastases  [25, 39–41] . Octreoscan or SPECT/CT 
may be helpful in somatostatin-receptor-positive lesions 
 [23, 42] , but when used alone lacks fine discrimination 
and cannot provide definitive anatomical localization. 
There is one report of a patient with two cardiac lesions 
detected by  18 F-DOPA-PET/CT, neither of which was vi-
sualized by echocardiography or octreoscan  [43] . It is 
likely that the more frequent use of  68 Ga-DOTATOC- 
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and  18 F DOPA-PET/CT will probably increase the preva-
lence of myocardial metastases. Ovarian metastases are 
either diagnosed by ultrasound if large in size, or by rou-
tine imaging such as MRI or CT scanning. In general, 
they are usually discovered incidentally and more fre-
quently by octreoscan or  68 Ga-DOTATOC-PET/CT.
Minimal Consensus Statement on Imaging
 MRI is the most sensitive method for detecting single and 
multiple brain metastases. It is recommended as part of the 
metastatic workup in patients with neuroendocrine carcinoma 
of the lung. Echocardiography is the most frequently used 
method for detecting myocardial metastases, followed by 
MRI, which should be undertaken in individuals in whom 
there is suspicion of cardiac metastases. Ovarian metastases 
are best defined by ultrasound and MRI. 
 Laboratory Tests 
 There are no specific laboratory tests to detect these 
metastatic sites.
 Pathology and Genetics 
 Pathological diagnosis of metastases is not mandatory 
if diagnosis is confirmed histologically by resection of
the primary tumor or a liver biopsy. Octreoscan or
 68 Ga-DOTATOC-PET/CT represent the main imaging 
methods for staging of the tumors and are helpful in iden-
tifying rare metastases such as neuroendocrine tumor 
 lesions. In cases of negative somatostatin-receptor scintig-
raphy, a second primary tumor as the cause for brain, 
ovarian or other rare metastases (e.g. breast, adrenal 
glands) should be considered. Specific biopsy of the rare 
metastatic lesion may occasionally be necessary to prove 
its neuroendocrine nature. Determination of the differen-
tiation status and tumor grading are pivotal in determin-
ing the therapeutic strategy. Patients should be classified 
according to the WHO system. The majority of tumors 
are classified as WHO group 2 grade G1 or G2; up to half 
of the patients with brain metastases, however, may be-
long to WHO group 3, grade G3. Overall, metastasis to the 
heart, brain and ovary indicates that such individuals are 
stage IV according to TNM classification criteria. There 
is no known predisposing genetic background for patients 
who develop rare metastases, and thus there is no need for 
germline DNA testing or genetic counseling.
 Minimal Consensus Statement on Pathology and 
Genetics 
In patients with confirmed histology of a primary NET, no 
additional pathological examination of rare metastatic sites is 
usually necessary. Indication of the proliferation index, as 
measured by labeling with Ki-67 and/or mitotic index of at 
least one tumor localization is mandatory to determine the ap-
propriate therapeutic strategy. There is no indication for ge-
netic testing.
 Surgery 
 In patients with rare metastases, surgery plays a pal-
liative role, except in poorly differentiated neuroendo-
crine carcinomas where chemotherapy is the appropriate 
treatment. Surgery is the method of choice for single 
brain metastases. The outcome seems to be superior if 
combined with external beam irradiation  [3] . Local sur-
gical excision is the treatment of choice in patients with 
symptomatic cardiac metastases. In asymptomatic pa-
tients, a ‘watch and wait’ strategy can be followed. There 
are no data on the impact of cardiac surgery on the sur-
vival rate of patients with myocardial metastases. Resec-
tion of ovarian metastases, including debulking surgery, 
is indicated to alleviate local symptoms due to mass effect 
or uncontrolled carcinoid syndrome. Cytoreductive sur-
gery of ovarian metastases may be of some benefit in the 
improvement of 5-year survival rates  [30] .
 Medical Therapy 
 Steroids are the primary symptomatic therapy for 
brain metastases and ameliorate brain edema. Cardiac 
metastases may require the administration of anti-ar-
rhythmic drugs (  -adrenoceptor blockers) and should be 
assessed by a cardiologist. Somatostatin analogs are the 
standard treatment for functioning tumors and are indi-
cated prior to other interventions/therapies for rare met-
 Minimal Consensus Statement on Surgery 
Surgery is indicated in patients with single brain metasta-
ses, usually of a well-differentiated nature, and can be consid-
ered in individual patients with multiple brain metastases. 
Surgery is recommended in patients with symptomatic cardiac 
metastasis and in ovarian metastases if they are locally symp-
tomatic or if carcinoid syndrome is present.
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astatic sites (see ENETS Guidelines on the medical treat-
ment of neuroendocrine tumors). Occasionally they are 
used in nonfunctioning tumors if they are somatostatin 
receptor positive, although data are limited to support 
their use here. Interferon-  can be used alternatively or 
in combination with somatostatin analogs. Chemothera-
py is used according to tumor origin, differentiation sta-
tus and biology. It is indicated in poorly differentiated 
(G3) neuroendocrine carcinomas; cisplatin-based regi-
mens represent the standard treatment. Temozolomide 
can be used as basic therapy in brain metastases originat-
ing from foregut tumors, but midgut tumors appear to be 
much less responsive and there is as yet limited experi-
ence (see ENETS Guidelines for foregut and poorly dif-
ferentiated neuroendocrine tumors).
 Minimal Consensus Statements on Medical Therapy 
Steroids are the standard treatment for brain metastases to 
obviate the consequences of edema or as prophylactic therapy 
prior to whole-brain irradiation. Medical treatment may be 
considered in symptomatic but inoperable cardiac metastases. 
Somatostatin analogs are recommended according to ENETS 
Guidelines in patients with functioning tumors and occasion-
ally in those with nonfunctioning tumors if they are SRS-pos-
itive. Interferon-  is used in individual patients as an alterna-
tive to or in combination with somatostatin analogs. Chemo-
therapy is indicated in poorly differentiated neuroendocrine 
carcinomas and in foregut tumors, depending on differentia-
tion and growth behavior (see ENETS Guidelines).
 External Beam Irradiation/Peptide Receptor 
Radionuclide Therapy 
 In patients with multiple brain metastases, external 
beam irradiation is the appropriate treatment  [1, 3, 4, 44] . 
It can be combined with surgery in individual cases, with 
the exception of poorly differentiated tumors. Systemic 
treatment is usually a better option as opposed to an ag-
gressive local approach, especially when a neurosurgical 
intervention is not mandatory for neurological deficits. 
External beam irradiation is reported to be used in some 
individuals with cardiac metastases; however, it is unlike-
ly to induce major responses in the myocardium  [26, 45, 
46] . There are no data available on the impact of irradia-
tion or peptide receptor radionuclide therapy (PRRT) on 
the management of brain, cardiac or ovarian metastases. 
PRRT either with yttrium-90- or lutetium-177-labeled 
somatostatin analogs may be used in individual patients, 
depending on the local availability for progressive disease 
and palliation of symptomatic disease. Tumor involve-
ment of the liver, lung and bones is usually the primary 
determinant for choosing PRRT rather than myocardial, 
cerebral or ovarian metastases; strong SRS uptake is nec-
essary when selecting patients for PRRT.
 Minimal Consensus Statements on External Beam 
Irradiation/PRRT 
Radiotherapy is indicated for multiple brain metastases. 
PRRT can be considered in individual patients with brain, car-
diac or ovarian metastases, depending on the specific indi-
vidual situation.
 Follow-Up 
 The follow-up intervals are highly variable depending 
on the clinical situation, functionality, differentiation 
status, growth characteristics and time since diagnosis. 
Intervals may vary, but generally follow-up should be tai-
lored to individual needs and is usually every 3 months. 
Involvement of critical organs like the brain and heart 
may require closer surveillance, especially after the initial 
diagnosis. In such circumstances, clinical follow-up may 
be recommended every month and follow-up visits in-
cluding imaging (MRI of the brain, echocardiography) 
every 3 months. In patients with ovarian metastases the 
follow-up is similar to that of patients with liver metasta-
ses and is mandated by the specific clinical situation. It 
may vary from every 3 months in progressive disease to 
every 6–12 months in stable disease.
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The time schedule for follow-up examinations depends on 
the individual clinical situation and ranges from 1 to 3 months 
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gressive disease or poorly differentiated neuroendocrine car-
cinoma to every 6 months. Follow-up visits in patients with 
ovarian metastases follow the same principles as for patients 
with hepatic metastasis.
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